References
Compston A, Lassmann H and McDonald I .The Story
of Multiple Sclerosis. McAlpine’s Multiple Sclerosis. 4th
ed. Churchill Livingstone, London (2006) 3-68.
Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua
B, Akhtar N, Al Hail H, D′souza A, Melikyan G, Imam
YZ, Osman Y, Elalamy O, Sokrab T, Kamran S, Ruiz
Miyares F and Ibrahim F. Prevalence, demographics
and clinical characteristics of multiple sclerosis in
Qatar. Mult. Scler. J. (2013) 19: 816–9.
Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi
M, Tabassi A, Ashrafi F, Ghaffarpor M, Sharifi S,
Delavar Kasmae H, Assarzadegan F, Arabahmadi
M and Behnam B. Health-related quality of life in
patients with relapsing-remitting multiple sclerosis
treated with subcutaneous interferon β-1a in Iran. Int.
J. Neurosci. (2017) 127: 501–7.
Yamout B, Barada W, Tohme RA, Mehio-Sibai A,
Khalifeh R and El-Hajj T. Clinical characteristics of
multiple sclerosis in Lebanon. J. Neurol. Sci. (2008)
270: 88–93.
Alroughani R, Ahmed SF and Al-Hashel J.
Demographics and clinical characteristics of multiple
sclerosis in Kuwait. Eur. Neurol. (2014) 72: 181–5.
Akhtar N, Elsetouhy A, Deleu D, Kamran S, Alhail
H, Elalamy O, Mesraoua B, Sokrab T, Kamil H,
Melikyan G, D′souza A, Osman Y and Imam Y. Newly
diagnosed multiple sclerosis in state of Qatar. Clin.
Neurol. Neurosurg. (2013) 115: 1333–7.
Multiple sclerosis in adults: management. National
(1)
(2)
(3)
(4)
(5)
(6)
(7)
Nabavi SM et al. / IJPR (2019), 18 (3): 1632-1638
1638
(11)
(12)
(13)
(8)
(9)
(10)
Institute for Health and Care Excellence. 2014 Oct
[cited 2018 Sep 26]; Available from: URL: https://
www.nice.org.uk/guidance/cg186.
Kleinschnitz C, Niemczyk G, Rehberg-Weber K and
Wernsdörfer C. Interferon Beta-1a (AVONEX®) as a
Treatment Option for Untreated Patients with Multiple
Sclerosis (AXIOM): A Prospective, Observational
Study. Int. J. Mol. Sci. (2015) 16: 15271-86.
Etemadifar M, Janghorbani M and Shaygannejad
V. Comparison of Betaferon, Avonex, and Rebif in
treatment of relapsing–remitting multiple sclerosis.
Acta. Neurol. Scand. (2006) 113: 283-7.
Nafissi S, Azimi A, Amini-Harandi A, Salami S and
Heshmat R. Comparing efficacy and side effects of a
weekly intramuscular biogeneric/biosimilar interferon
beta-1a with Avonex in relapsing remitting multiple
sclerosis: A double blind randomized clinical trial.
Clin. Neurol. Neurosurg. (2012) 114: 986-9.
Graziella Filippini, L. Interferons in relapsing remitting
multiple sclerosis: a systematic review. Lancet (2003)
361: 545-52.
De Stefano N, Sormani MP, Stubinski B, Blevins G,
Drulovic JS, Issard D, Shotekov P and Gasperini C.
Efficacy and safety of subcutaneous interferon beta1a in relapsing–remitting multiple sclerosis: Further
outcomes from the Improve study. J. Neurol. Sci.
(2012) 312: 97-101.
AVONEX® (interferon beta-1a) Intramuscular
Injection, Full Prescribing Information. Availble
from: URL: http://www.avonex.com/pdfs/Avonex_
Prescribing_Information.pdf.